Joan L Walker1, Mark F Brady2, Lari Wenzel3, Gini F Fleming4, Helen Q Huang2, Paul A DiSilvestro5, Keiichi Fujiwara6, David S Alberts7, Wenxin Zheng8, Krishnansu S Tewari3, David E Cohn9, Matthew A Powell10, Linda Van Le11, Susan A Davidson12, Heidi J Gray13, Peter G Rose14, Carol Aghajanian15, Tashanna Myers16, Angeles Alvarez Secord17, Stephen C Rubin18, Robert S Mannel1. 1. 1 University of Oklahoma Health Sciences Center, Oklahoma City, OK. 2. 2 Roswell Park Cancer Institute, Buffalo, NY. 3. 3 University of California, Irvine, Medical Center, Orange, CA. 4. 4 The University of Chicago Medicine, Chicago, IL. 5. 5 Women and Infants Hospital, Providence, RI. 6. 6 Saitama Medical University International Medical Center, Hidaka-Shi, Japan. 7. 7 The University of Arizona Cancer Center, Tucson, AZ. 8. 8 The University of Arizona, Tucson, AZ. 9. 9 The Ohio State University, Columbus, OH. 10. 10 Washington University in St Louis, St Louis, MO. 11. 11 University of North Carolina at Chapel Hill, Chapel Hill, NC. 12. 12 University of Colorado, Aurora, CO. 13. 13 University of Washington School of Medicine, Seattle, WA. 14. 14 Cleveland Clinic Foundation, Cleveland, OH. 15. 15 Memorial Sloan Kettering Cancer Center, New York, NY. 16. 16 University of Connecticut, Storrs, CT. 17. 17 Duke University Health System, Durham, NC. 18. 18 University of Pennsylvania, Philadelphia, PA.
Abstract
PURPOSE: To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma. METHODS: Eligible patients were randomly assigned to six cycles of IV paclitaxel 80 mg/m2 once per week with intravenous (IV) carboplatin area under the curve 6 (IV carboplatin) versus IV paclitaxel 80 mg/m2 once per week with IP carboplatin area under the curve 6 (IP carboplatin) versus once every 3 weeks IV paclitaxel 135 mg/m2 over 3 hours day 1, IP cisplatin 75 mg/m2 day 2, and IP paclitaxel 60 mg/m2 day 8 (IP cisplatin). All participants received bevacizumab 15 mg/kg IV every 3 weeks in cycles 2 to 22. RESULTS: A total of 1,560 participants were enrolled and had 84.8 months of follow-up. The median PFS duration was 24.9 months in the IV carboplatin arm, 27.4 months in the IP carboplatin arm, and 26.2 months in the IP cisplatin arm. For the subgroup of 1,380 patients with stage II/III and residual disease of 1 cm or less, median PFS was 26.9 (IV-carboplatin), 28.7 (IP-carboplatin), and 27.8 months (IP cisplatin), respectively. Median PFS for patients with stage II/III and no residual disease was 35.9, 38.8, and 35.5 months, respectively. Median overall survival for all enrolled was 75.5, 78.9, and 72.9 months, respectively, and median overall survival for stage II/III with no gross residual disease was 98.8 months, 104.8 months, and not reached. Mean patient-reported Functional Assessment of Cancer Therapy neurotoxicity scores (Gynecologic Oncology Group) were similar for all arms, but the mean Trial Outcome Index of the Functional Assessment of Cancer Therapy-Ovary scores during chemotherapy were statistically worse in the IP cisplatin arm. CONCLUSION: Compared with the IV carboplatin reference arm, the duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab and was better tolerated than IP cisplatin.
PURPOSE: To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma. METHODS: Eligible patients were randomly assigned to six cycles of IV paclitaxel 80 mg/m2 once per week with intravenous (IV) carboplatin area under the curve 6 (IV carboplatin) versus IV paclitaxel 80 mg/m2 once per week with IP carboplatin area under the curve 6 (IP carboplatin) versus once every 3 weeks IV paclitaxel 135 mg/m2 over 3 hours day 1, IP cisplatin 75 mg/m2 day 2, and IP paclitaxel 60 mg/m2 day 8 (IP cisplatin). All participants received bevacizumab 15 mg/kg IV every 3 weeks in cycles 2 to 22. RESULTS: A total of 1,560 participants were enrolled and had 84.8 months of follow-up. The median PFS duration was 24.9 months in the IV carboplatin arm, 27.4 months in the IP carboplatin arm, and 26.2 months in the IP cisplatin arm. For the subgroup of 1,380 patients with stage II/III and residual disease of 1 cm or less, median PFS was 26.9 (IV-carboplatin), 28.7 (IP-carboplatin), and 27.8 months (IP cisplatin), respectively. Median PFS for patients with stage II/III and no residual disease was 35.9, 38.8, and 35.5 months, respectively. Median overall survival for all enrolled was 75.5, 78.9, and 72.9 months, respectively, and median overall survival for stage II/III with no gross residual disease was 98.8 months, 104.8 months, and not reached. Mean patient-reported Functional Assessment of Cancer Therapy neurotoxicity scores (Gynecologic Oncology Group) were similar for all arms, but the mean Trial Outcome Index of the Functional Assessment of Cancer Therapy-Ovary scores during chemotherapy were statistically worse in the IP cisplatin arm. CONCLUSION: Compared with the IV carboplatin reference arm, the duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab and was better tolerated than IP cisplatin.
Authors: Lindsey A Torre; Britton Trabert; Carol E DeSantis; Kimberly D Miller; Goli Samimi; Carolyn D Runowicz; Mia M Gaudet; Ahmedin Jemal; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2018-05-29 Impact factor: 508.702
Authors: K Basen-Engquist; D Bodurka-Bevers; M A Fitzgerald; K Webster; D Cella; S Hu; D M Gershenson Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Don S Dizon; Michael W Sill; Natalie Gould; Stephen C Rubin; S Diane Yamada; Robert L Debernardo; Robert S Mannel; Eric L Eisenhauer; Linda R Duska; Paula M Fracasso Journal: Gynecol Oncol Date: 2011-08-05 Impact factor: 5.482
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: John K Chan; Mark F Brady; Richard T Penson; Helen Huang; Michael J Birrer; Joan L Walker; Paul A DiSilvestro; Stephen C Rubin; Lainie P Martin; Susan A Davidson; Warner K Huh; David M O'Malley; Matthew P Boente; Helen Michael; Bradley J Monk Journal: N Engl J Med Date: 2016-02-25 Impact factor: 91.245
Authors: Alexi A Wright; Angel Cronin; Dana E Milne; Michael A Bookman; Robert A Burger; David E Cohn; Mihaela C Cristea; Jennifer J Griggs; Nancy L Keating; Charles F Levenback; Gina Mantia-Smaldone; Ursula A Matulonis; Larissa A Meyer; Joyce C Niland; Jane C Weeks; David M O'Malley Journal: J Clin Oncol Date: 2015-08-03 Impact factor: 44.544
Authors: Lisa M Landrum; James Java; Cara A Mathews; Grainger S Lanneau; Larry J Copeland; Deborah K Armstrong; Joan L Walker Journal: Gynecol Oncol Date: 2013-04-08 Impact factor: 5.482
Authors: Amit M Oza; Adrian D Cook; Jacobus Pfisterer; Andrew Embleton; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Tjoung-Won Park-Simon; Gordon Rustin; Florence Joly; Mansoor R Mirza; Marie Plante; Michael Quinn; Andrés Poveda; Gordon C Jayson; Dan Stark; Ann Marie Swart; Laura Farrelly; Richard Kaplan; Mahesh K B Parmar; Timothy J Perren Journal: Lancet Oncol Date: 2015-06-23 Impact factor: 41.316
Authors: Willemien J van Driel; Simone N Koole; Karolina Sikorska; Jules H Schagen van Leeuwen; Henk W R Schreuder; Ralph H M Hermans; Ignace H J T de Hingh; Jacobus van der Velden; Henriëtte J Arts; Leon F A G Massuger; Arend G J Aalbers; Victor J Verwaal; Jacobien M Kieffer; Koen K Van de Vijver; Harm van Tinteren; Neil K Aaronson; Gabe S Sonke Journal: N Engl J Med Date: 2018-01-18 Impact factor: 91.245
Authors: Joanne O'Dwyer; Roisin E O'Cearbhaill; Robert Wylie; Saoirse O'Mahony; Michael O'Dwyer; Garry P Duffy; Eimear B Dolan Journal: Adv Ther (Weinh) Date: 2020-08-16
Authors: Krishnansu S Tewari; Robert A Burger; Danielle Enserro; Barbara M Norquist; Elizabeth M Swisher; Mark F Brady; Michael A Bookman; Gini F Fleming; Helen Huang; Howard D Homesley; Jeffrey M Fowler; Benjamin E Greer; Matthew Boente; Sharon X Liang; Chenglin Ye; Carlos Bais; Leslie M Randall; John K Chan; J Stuart Ferriss; Robert L Coleman; Carol Aghajanian; Thomas J Herzog; Philip J DiSaia; Larry J Copeland; Robert S Mannel; Michael J Birrer; Bradley J Monk Journal: J Clin Oncol Date: 2019-06-19 Impact factor: 44.544
Authors: Karen A Cadoo; Rachel N Grisham; Roisin E O'Cearbhaill; Nicole N Boucicaut; Melissa Henson; Alexia Iasonos; Qin Zhou; Debra M Sarasohn; Jacqueline Gallagher; Sara Kravetz; Dmitriy Zamarin; Vicky Makker; Paul J Sabbatini; William P Tew; Carol Aghajanian; Jason A Konner Journal: Gynecol Oncol Date: 2020-01-17 Impact factor: 5.482
Authors: Andres Redondo; Ana Oaknin; Maria Jesus Rubio; Maria-Pilar Barretina-Ginesta; Ana de Juan; Luis Manso; Ignacio Romero; Cristina Martin-Lorente; Andres Poveda; Antonio Gonzalez-Martin Journal: J Ovarian Res Date: 2021-05-26 Impact factor: 4.234